| Catalog No. | HW305026 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Functional assay, Research in vivo |
|---|
| Isotype | Vascular Endothelial Growth Factor Receptor 3 fusion protein with IgG1 Fc Fragment. |
|---|
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
Vascular endothelial growth factor C, VEGFC, Flt4-L, VEGF-C, Vascular endothelial growth factor-related protein, VRP, Flt4 ligand, Vascular endothelial growth factor D, VEGF-D, FIGF, VEGFD, c-Fos-induced growth factor |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
P49767 & O43915 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names | OPT-302, solubleVEGFR-3, sozinibercept, VGX-300 |
|---|
| Background | Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats.
|
|---|
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
中文
English
